ArticleP & T : a peer-reviewed journal for formulary management2015
A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
Article in P & T : a peer-reviewed journal for formulary management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis.Current atherosclerosis reports · 2020Pooled it
- Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms.Nutrients · 2020Trial
- Comparative Risk of Atrial Fibrillation Onset in Statin-Treated Patients Initiating Icosapent Ethyl and Omega-3 Acid Ethyl Esters: A Retrospective Cohort Study.Journal of the American Heart Association · 2025Article
- Article
- The EPA oxylipin, 12-HEPE, directly regulates human platelet activity.Journal of lipid research · 2025Article
- The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention.Current atherosclerosis reports · 2025Review
- Effect of Omega-3 Fatty Acid Supplementation on Cellular Lipid Profile: A Case Series.Journal of chiropractic medicine · 2025Article
- Comprehensive Approach to Medical Nutrition Therapy in Patients with Type 2 Diabetes Mellitus: From Diet to Bioactive Compounds.Antioxidants (Basel, Switzerland) · 2023Review
- Rapid Quantitation of Adulterants in Premium Marine Oils by Raman and IR Spectroscopy: A Data Fusion Approach.Molecules (Basel, Switzerland) · 2022Article
- Prevention and Reversal of Morbidity in Today's Cardiovascular Patient: Role of Lifestyle Modification and Nutrition in the Current Era.Current cardiology reports · 2021Review
- Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment.Current atherosclerosis reports · 2021Review
- Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction.Current atherosclerosis reports · 2020Review
- Oxidized Lipids and Lipoprotein Dysfunction in Psoriasis.Journal of psoriasis and psoriatic arthritis · 2020Article
- Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord.Annual review of nutrition · 2020Review
- Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.Advances in therapy · 2020Review
- Omega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders.CNS & neurological disorders drug targets · 2019Review
- Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care.Journal of the Endocrine Society · 2018Review
- Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids.Current atherosclerosis reports · 2017Review
- 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.Current pharmaceutical design · 2017Review
- Docosahexaenoic Acid Supplementation is Not Anti-Inflammatory in Adipose Tissue of Healthy Obese Postmenopausal Women.International journal of nutrition · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An estimated 25% of adults in the United States have elevated triglyceride (TG) levels. This is of particular concern given the evidence for a causal role of TG in the pathway of cardiovascular (CV) disease. Approved prescription omega-3 fatty acid products (RxOM3FAs) contain the long-chain fatty acids docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA) and are effective options for the treatment of high TG levels. RxOM3FAs that contain both EPA and DHA include omega-3-acid ethyl esters (ethyl esters of EPA and DHA; brand and generic products) and omega-3-carboxylic acids (free fatty acids primarily composed of EPA and DHA), while the RxOM3FA icosapent ethyl (the ethyl ester of EPA) contains EPA only. All RxOM3FA products produce substantial TG reduction and other beneficial effects on atherogenic lipid and inflammation-related parameters, blood pressure, and heart rate variability, but products that contain DHA may raise low-density lipoprotein-cholesterol (LDL-C). This commentary provides an overview of hypertriglyceridemia while summarizing the pharmacology, efficacy, and safety of prescription RxOM3FAs.
Indexed as
Identifiers
26681905PMC4671468W2418099252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.